Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4528-4528
Author(s):  
Hink Boer ◽  
Johannes H Proost ◽  
Janine Nuver ◽  
Sophie Bunskoek ◽  
Joyce Q. Gietema ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Late Effects ◽  
Compartment Model ◽  
Population Pharmacokinetic ◽  
Serum Samples ◽  
Time Points ◽  
Two Compartment Model ◽  
Testicular Cancer Survivors

4528 Background: Successful platinum(Pt)-based chemotherapy for testicular cancer (TC) comes at the price of late cardiovascular morbidity and neurotoxicity. Damage induced by circulating Pt could be an etiological mechanism. We investigated the relation between circulating Pt and late effects. Methods: In 96 consecutive TC patients (med age 29 [17-53] at chemotherapy), 3 serum samples and a 24h-urine sample were collected on several time-points med 5 yrs (1-13) after treatment. Pt concentrations ([Pt]) were measured with a sensitive voltammetric method (Lancet 2000, 355:1075). Measured [Pt] combined with cisplatin dose, age, weight and height were analyzed simultaneously to construct a population pharmacokinetic (PK) model using NONMEM. Based on the PK parameters of each patient, individual [Pt] at 1, 3, 5, 10 yrs after start and AUC were calculated. Cardiovascular status, paresthesia and markers of vascular damage were assessed after a med follow-up (FU) of 9 yrs (3-15). Results: Decay of [Pt] was best described by a two compartment model. Mean terminal T1/2 was 3.7 (±0.3) yrs. At all time-points [Pt] correlated with cisplatin dose and renal function during treatment. [Pt] at 3 yrs correlated with systolic blood pressure (BP) (r=.32, p<0.01) and creatinine clearance (CRCL) (r=-.25, p=0.02) at FU. Patients with increased BP had higher Pt AUCs than patients with normal BP (table). Pt AUCs were higher in patients with paresthesia (table). Conclusions: Known late effects of cisplatin-based chemotherapy such as hypertension and paresthesia are related to higher circulating [Pt]. Long-term exposure to Pt is involved in healthy tissue damage in TC survivors. [Table: see text]

scholarly journals Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors

2015 ◽  
Vol 26 (10) ◽  
pp. 2133-2140 ◽  
Author(s):  
M. Sprauten ◽  
H.S. Haugnes ◽  
M. Brydøy ◽  
C. Kiserud ◽  
T. Tandstad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Chronic Fatigue ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

scholarly journals Long-Term Follow Up of the Erectile Function of Testicular Cancer Survivors

2019 ◽  
Vol 10 ◽  
Author(s):  
Francesco Pallotti ◽  
Alessandra Petrozzi ◽  
Francesco Cargnelutti ◽  
Antonio Francesco Radicioni ◽  
Andrea Lenzi ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Erectile Function ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

7172 Feelings of loss and shame after having lost a testicle: a population-based long-term follow-up of testicular-cancer survivors

2009 ◽  
Vol 7 (2) ◽  
pp. 445
Author(s):  
J.S. Skoogh ◽  
G.S. Steineck ◽  
E.C.S. Cavallin-Ståhl ◽  
U.O. Ulrica Olofsson ◽  
M.L. Magnus Lindwall ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Population Based ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

Detection of second malignancies during long-term follow-up of testicular cancer survivors

Cancer ◽  
2011 ◽  
Vol 117 (18) ◽  
pp. 4212-4218 ◽  
Author(s):  
Tomas Buchler ◽  
Petra Kubankova ◽  
Ludmila Boublikova ◽  
Zuzana Donatova ◽  
Martin Foldyna ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Second Malignancies ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

scholarly journals Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors

2018 ◽  
Vol 57 (10) ◽  
pp. 1392-1400 ◽  
Author(s):  
Line V. Hjelle ◽  
Per O. M. Gundersen ◽  
Ragnhild Hellesnes ◽  
Mette Sprauten ◽  
Marianne Brydøy ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Late Effects ◽  
Testicular Cancer Survivors

Long-term complications of platinum in testicular cancer survivors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4589-4589
Author(s):  
J. H. Oh ◽  
D. D. Baum ◽  
J. Ensor ◽  
S. Pham ◽  
M. D. Muddiman ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Treatment Modalities ◽  
Platinum Based Chemotherapy ◽  
Blood Pressure Treatment ◽  
The Mean ◽  
Testicular Cancer Survivors ◽  
All Treatment

4589 Background: Long-term medical complications of platinum have become a major priority in the care of testicular cancer survivors. This study aimed to describe the prevalence of these complications from platinum-based therapy in American testicular cancer survivors. Methods: Testicular cancer survivors with no evidence of disease for at least 2 years were interviewed, had lab tests, and charts reviewed. Demographics, comorbidities, blood pressure, treatment, and outcomes were compared between all treatment modalities. NHANES 2002 and NHIS 2004 were used to obtain national estimates. Results: The mean age was 41 years; 72.7 % had nonseminoma, 96.5% had orchiectomy, 21.0% received radiation (XRT), and 82.5% platinum. The mean follow-up was 8.4 years. There was no statistical difference in the rates of Coronary Artery Disease (CAD), hyperlipidemia, hypertension (HTN), renal insufficiency (RI), or hypomagnesemia (see table ). There was a trend toward an increase in hyperlipidemia at follow-up compared to initial visit in all treatment groups but HTN increased only in those who did not receive platinum. Conclusion: Excluding HTN, we observed a trend toward an increase in the prevalence of RI, hypomagnesemia, hyperlipidemia, and CAD among patients who received platinum when compared to their baseline rates. Similar to a recent study by Huddart et al, we saw a trend toward higher risk of developing CAD in those who received both platinum and XRT. These findings suggest that hyperlipidemia and HTN may be more related to orchiectomy or the germ cell tumor itself than being a complication of platinum. Further prospective cohort studies with a larger group of survivors who have not received platinum are warranted to determine if HTN and hyperlipidemia are true complications of platinum-based chemotherapy. [Table: see text] No significant financial relationships to disclose.

Long-term platinum (Pt) change and its associations with cisplatin-related late effects in testicular cancer survivors (TCSs).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e22067-e22067
Author(s):  
Hege Sagstuen Haugnes ◽  
Line Veronika Hjelle ◽  
Per Ole Gundersen ◽  
Ragnhild Hellesnes ◽  
Mette Sprauten ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Late Effects ◽  
Testicular Cancer Survivors

scholarly journals Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors

2015 ◽  
Vol 26 (11) ◽  
pp. 2305-2310 ◽  
Author(s):  
H. Boer ◽  
J.H. Proost ◽  
J. Nuver ◽  
S. Bunskoek ◽  
J.Q. Gietema ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Late Effects ◽  
Testicular Cancer Survivors

Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up

2012 ◽  
Vol 30 (30) ◽  
pp. 3752-3763 ◽  
Author(s):  
Hege S. Haugnes ◽  
George J. Bosl ◽  
Hink Boer ◽  
Jourik A. Gietema ◽  
Marianne Brydøy ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Testicular Cancer ◽  
Germ Cell ◽  
Late Effects ◽  
Current Status ◽  
Malignant Neoplasms ◽  
Treatment Type ◽  
Increased Risk

Germ cell testicular cancer (TC) represents a malignancy with high cure rates. Since the introduction of cisplatin-based chemotherapy in the late 1970s, the 5-year survival rate has increased considerably, and it is currently above 95%. Because TC is usually diagnosed before the age of 40 years, these men can expect to live for another 40 to 50 years after being successfully treated. This success, however, is hampered by an increased risk of long-term and late effects of treatment. Secondary malignant neoplasms and cardiovascular disease represent the most common potentially life-threatening late effects, typically occurring more than 10 years after treatment. Other long-term effects include pulmonary toxicity, nephrotoxicity, neurotoxicity, decreased fertility, hypogonadism, and psychosocial problems. The incidence and time to onset of these various adverse effects vary according to treatment type and intensity. There is still little knowledge about underlying mechanisms and genetic susceptibility of the various adverse effects. Apart from treatment burden, it is not yet possible to identify patients who are at high risk for certain late effects after TC treatment. In this clinical review, we present the current status regarding different somatic and psychosocial long-term late effects after treatment for TC, based on Medline searches and our own research. Moreover, we postulate recommendations for general medical evaluations that should begin after treatment is completed and continue during follow-up.

Sign in / Sign up

Export Citation Format

Share Document